See the DrugPatentWatch profile for Tobi
What is Tobi Podhaler (tobramycin inhalation powder)?
Tobi Podhaler is a brand of inhaled tobramycin in dry-powder form used to treat people with cystic fibrosis who have chronic lung infection with Pseudomonas aeruginosa [1]. Patients inhale the medicine through the Podhaler device as a powder treatment cycle (the drug is taken in repeating on/off cycles) [1].
How does it compare with Tobi (tobramycin solution) or other inhaled tobramycin products?
Tobi Podhaler delivers tobramycin as an inhalation powder, while some other products deliver tobramycin as an inhaled liquid solution using a nebulizer. The key practical difference is the delivery method (Podhaler inhaler vs nebulizer), not the underlying antibiotic (tobramycin) [1].
How is it used—what are the usual dosing cycles?
Tobi Podhaler is prescribed in repeating treatment cycles rather than continuously. The label includes an “on/off” schedule for inhaled tobramycin cycles in cystic fibrosis patients with chronic Pseudomonas infection [1].
Who should be careful or talk to a clinician before starting?
As an aminoglycoside antibiotic given by inhalation, tobramycin can raise concerns about effects on hearing and kidney function, so clinicians typically monitor for these risks in patients using inhaled tobramycin products. People should follow their prescribing clinician’s monitoring plan and report symptoms that could suggest hearing or balance problems [1].
What side effects do patients commonly report?
Common side effects can include cough, changes in voice, throat irritation, and other inhalation-related symptoms, since the drug is delivered directly to the lungs. Patients should also report any worsening breathing symptoms or suspected allergic reactions [1].
What if someone is switching to or from Tobi Podhaler?
Switching between inhaled tobramycin formulations (powder inhaler vs nebulized solution) generally involves confirming the prescription, the delivery technique, and the cycle schedule. The device and inhalation steps matter for getting the intended dose. Patients should receive clear instructions for using the Podhaler device and verify they are using the correct product for their regimen [1].
Sources
- FDA label for TOBI PODHALER (tobramycin inhalation powder). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205923